BDBulin Du

Bulin Du

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bulin Du has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Yaming Li

    Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, People’s Republic of China

    6 shared publications
  • Xuena Li

    Department of Nuclear Medicine The First Hospital of China Medical University Shenyang China

    4 shared publications
  • Yan Cui

    Department of Nuclear Medicine, The First Hospital of China Medical University , No. 155 Nanjing St, Shenyang 110001 , China

    3 shared publications
  • Guanghui Liu

    Department of Nuclear Medicine, The First Hospital of China Medical University , No. 155 Nanjing St, Shenyang 110001 , China

    2 shared publications
  • Xuena Li

    Department of Nuclear Medicine, the First Hospital of China Medical University, Shenyang, China

    2 shared publications
  • Chunrong Qu

    Molecular Imaging Program at Stanford (MIPS) Canary Center at Stanford for Cancer Early Detection Department of Radiology and Bio‐X Program School of Medicine Stanford University Palo Alto CA 94305‐5484 USA

    1 shared publication

Latest Publications

  • Open Access

    Multimodality imaging of a rare synchronous double primary cardiac leiomyosarcoma

    by Bulin Du, Yan Cui, Guanghui Liu, Yaming Li, Xuena Li

    Bulin Du, Yan Cui, Guanghui Liu, Yaming Li, Xuena Li; Multimodality imaging of a rare synchronous double primary cardiac leiomyosarcoma, European Heart Journal


  • Open Access

    The long noncoding RNA HOXA11‐AS promotes lung adenocarcinoma proliferation and glycolysis via the microRNA‐148b‐3p/PKM2 axis

    by Wenkun Chen, Xuena Li, Bulin Du, Yan Cui, Yu Ma, Yaming Li

    Background: Lung cancer is the most common malignancy in the world and a growing number of researches have focused on its metabolic characteristics. Studies have shown that the long non‐coding RNA (lncRNA) HOXA11‐AS is aberrantly expressed in many tumors. However, the role of HOXA11‐AS in lung adenocarcinoma (LUAD) glycolysis and other energy metabolism pathways has not been characterized.Method: The mRNA levels of HOXA11‐AS, microRNA‐148b‐3p (miR‐148b‐3p), and pyruvate kinase M2 (PKM2) were detected using qRT‐PCR. The expression levels of proteins were measured using immunohistochemistry and western blot. The CCK‐8, EdU, and colony formation assays were used to assess proliferation. Glycolytic changes were assessed by measuring lactate production, ATP production, and 18F‐FDG uptake. Bioinformatics analysis and dual‐luciferase reporter assays were used to characterize the relationship between HOXA11‐AS, miR‐148b‐3p, and PKM2. Proliferation and glycolytic changes were analyzed in xenograft tumor experiments using Micro‐PET imaging after downregulation of HOXA11‐AS in vivo.Results: The expression of HOXA11‐AS was markedly increased in LUAD, and was strongly associated with a poor prognosis. In addition, HOXA11‐AS promoted proliferation and glycolysis in LUAD, and miR‐148b‐3p inhibited proliferation and glycolysis in LUAD. Mechanistically, HOXA11‐AS positively regulated PKM2 expression by binding to miR‐148b‐3p, thereby promoting LUAD proliferation and glycolysis. In addition, HOXA11‐AS inhibited LUAD xenograft growth and glycolysis via upregulation of miR‐148b‐3p expression and downregulation of PKM2 expression in vivo.Conclusions: These results showed that HOXA11‐AS enhanced LUAD proliferation and glycolysis via the miR‐148b‐3p/PKM2 axis. The findings in this paper expanded our understanding of the molecular mechanisms of LUAD tumorigenesis and glycolysis and showed that HOXA11‐AS could be useful as a diagnostic and prognostic marker for LUAD. 18F‐FDG PET/CT can be used to visually evaluate the therapeutic effect of targeting HOXA11‐AS.


  • Open Access

    Can18F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer? A systematic review and meta-analysis

    by Bulin Du, Shu Wang, Yan Cui, Guanghui Liu, Xuena Li, Yaming Li

    Objectives: This study aimed to explore the diagnostic significance of18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC).Design: A systematic review and meta-analysis.Data sources: The PubMed, EMBASE and Cochrane library databases were searched from the earliest available date to December 2020.Eligibility criteria for selecting studies: The review included primary studies that compared the mean maximum of standard uptake value (SUVmax) between wild-type and mutantEGFR, and evaluated the diagnostic value of18F-FDG PET/CT using SUVmaxfor prediction ofEGFRstatus in patients with NSCLC.Data extraction and synthesis: The main analysis was to assess the sensitivity and specificity, the positive diagnostic likelihood ratio (DLR+) and DLR−, as well as the diagnostic OR (DOR) of SUVmaxin prediction ofEGFRmutations. Each data point of the summary receiver operator characteristic (SROC) graph was derived from a separate study. A random effects model was used for statistical analysis of the data, and then diagnostic performance for prediction was further assessed.Results: Across 15 studies (3574 patients), the pooled sensitivity for18F-FDG PET/CT was 0.70 (95% CI 0.60 to 0.79) with a pooled specificity of 0.59 (95% CI 0.52 to 0.66). The overall DLR+ was 1.74 (95% CI 1.49 to 2.03) and DLR− was 0.50 (95% CI 0.38 to 0.65). The pooled DOR was 3.50 (95% CI 2.37 to 5.17). The area under the SROC curve was 0.68 (95% CI 0.64 to 0.72). The likelihood ratio scatter plot based on average sensitivity and specificity was in the lower right quadrant.Conclusion: Meta-analysis results showed18F-FDG PET/CT had low pooled sensitivity and specificity. The low DOR and the likelihood ratio scatter plot indicated that18F-FDG PET/CT should be used with caution when predictingEGFRmutations in patients with NSCLC.


  • Radiolabeled Peptides for SPECT and PET Imaging in the Detection of Breast Cancer: Preclinical and Clinical Perspectives

    by Hao Fu, Bulin Du, Zijun Chen, Yesen Li

    Breast cancer is the most common cancer in women worldwide. Due to the heterogeneous nature of breast cancer, the optimal treatment and expected response for each patient may not necessarily be universal. Molecular imaging techniques could play an important role in the early detection and targeted therapy evaluation of breast cancer. This review focuses on the development of peptides labeled with SPECT and PET radionuclides for breast cancer imaging. We summarized the current status of radiolabeled peptides for different receptors in breast cancer. The characteristics of radionuclides and major techniques for peptide labeling are also briefly discussed.


  • An IR820 Dye–Protein Complex for Second Near‐Infrared Window and Photoacoustic Imaging

    by Bulin Du, Chunrong Qu, Kun Qian, Ying Ren, Yesen Li, Xiaohong Cui, Shuqing He, Yifan Wu, Timothy Ko, Ruiqi Liu, et al.

    Recently, much attention has been focused on the development of second near‐infrared window (NIR‐II, 1000–1700 nm) fluorescence imaging because of its reduced scattering, minimal absorption, and negligible autofluorescence. NIR‐II bioimaging allows the visualization of deep anatomical features with an unprecedented degree of clarity. In addition to the construction of a variety of new NIR‐II fluorophores, using a fluorescence tail emission greater than 1000 nm for conventional NIR‐I dyes represents a promising strategy for developing an NIR‐II imaging technique. Herein, the authors report tailoring a supramolecular assembly of human serum albumin (HSA) protein complexed with a sulfonated NIR‐I organic dye (IR820) to produce a brilliant 21‐fold increase in fluorescence for NIR‐II imaging. In vivo NIR‐II imaging with IR820–HSA allows noninvasive and dynamic visualization and monitoring of physiological and pathological conditions of the vascular system, lymphatic drainage system, and tumor‐bearing mice, as well as image‐guided tumor resection with high spatial and temporal resolution. Furthermore, photoacoustic imaging (PAI) of IR820–HSA in mouse tumor models also demonstrate good tumor accumulation. Overall, an IR820–protein complex with high biocompatibility can be easily constructed using a conventional NIR‐I dye that provides a new theranostic tool with high clinical translation potential.


  • Open Access

    Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [ 18 F]FDG

    by Bulin Du, Tong Sun, Xuena Li, Yao Diao, Yaming Li

    Subunit of isocitrate dehydrogenase 3 (IDH3a) as upstream of the hypoxia‐inducible factor was reported highly expressed in malignant tumors, playing an important role in glucose metabolism reprogramming. As one of rate‐limiting enzyme in the Krebs cycle, whether high expression of IDH3a affects glucose uptake in tumors has not been elucidated. This study was aimed to investigate the relationship between IDH3a expression and tumor glucose uptake. Sixty‐five patients who underwent 2‐[ 18 F]‐2‐deoxy‐D‐glucose ([ 18 F]‐FDG) positron emission tomography/computed tomography (PET/CT) imaging before surgery and pathologically diagnosed as lung adenocarcinoma were included. All patients were divided into high (n = 31) and low (n = 34) groups according IDH3a expression by immunohistochemistry. Comparatively higher [ 18 F]‐FDG uptake was found in high IDH3a expression group. Glucose transporter 1 (GLUT1) level was demonstrated to correlate with IDH3a expression, but not for hexokinase 2 (HK2). Furthermore, A549 and H1299 cells experiment showed, the expression of p‐AKT and GLUT1 were significantly downregulated after IDH3a interference. The cellular uptake of [ 18 F]‐FDG and lactate production were significantly reduced in treatment group. In summary, high expression of IDH3a in lung adenocarcinoma patients is associated with higher glucose uptake. IDH3a targets AKT‐GLUT1 pathway to affect glucose uptake and metabolites in lung adenocarcinoma.


  • Open Access

    Thyroid Remnant Estimation by Diagnostic Dose Scintigraphy or Scintigraphy after Thyroidectomy: A Comparison with Therapeutic Dose Imaging

    by Guanghui Liu, Na Li, Xuena Li, Song Chen, Bulin Du, Yaming Li

    In this clinical study, we have compared routine diagnostic dose131I scan andTcO4-99mthyroid scintigraphy with therapeutic dose131I imaging for accurate thyroid remnant estimation after total thyroidectomy. We conducted a retrospective review of the patients undergoing total thyroidectomy for differentiated thyroid carcinoma (DTC) and subsequently receiving radioactive iodine (RAI) treatment to ablate remnant thyroid tissue. All patients had therapeutic dose RAI whole body scan, which was compared with that of diagnostic dose RAI,TcO4-99mthyroid scan, and ultrasound examination. We concluded that therapeutic dose RAI scan reveals some extent thyroid remnant in all DTC patients following total thyroidectomy. Diagnostic RAI scan is much superior to ultrasound andTcO4-99mthyroid scan for the postoperative estimation of thyroid remnant. Ultrasound andTcO4-99mthyroid scan provide little information for thyroid remnant estimation and, therefore, would not replace diagnostic RAI scan.